NCT00111579View on ClinicalTrials.gov

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

CAIV-T

A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.

OTHER

TIV

A total vol. of 0.25 will be administered intramuscularly for each of two doeses.

Trial Locations (5)

84041

Wee Care Pediatrics, Layton

84062

Alpine Pediatrics, Pleasant Grove

84095

Families First Pediatrics, South Jordan

84405

Bear Care Pediatrics, Ogden

84604

Utah Valley Pediatrics, Provo

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT00111579 - Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV) | Biotech Hunter | Biotech Hunter